Related Experiment Video
Updated: May 23, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
Anti-tumor necrosis factor-α agents in noninfectious uveitis
Julie Gueudry1, Phuc LeHoang, Bahram Bodaghi
1Department of Ophthalmology, Charles Nicolle University Hospital, Rouen, France.
Abstract:
Anti-tumor necrosis factor-α (anti-TNF-α) agents represent a major breakthrough for the therapeutic management of different autoimmune conditions. Noninfectious uveitis may lead to various sight threatening complications. Hence, from extrapolation of the benefit observed in autoimmune systemic diseases, anti-TNF-α agents are widely used in the treatment of noninfectious uveitis. However, their use remains mostly 'off-label' in this indication, and the lack of evidence from randomized controlled studies limits a rationale choice. This review gives an update on the management of uveitis with TNF-α inhibitors, highlighting important issues, including initiation time, type of molecule, duration of therapy but also major adverse events.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Immunotherapy
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Angle Closure Glaucoma: Treatment

